Vilanterol (BioDeep_00000730163)
代谢物信息卡片
Vilanterol
化学式: C24H33Cl2NO5 (485.17356680000006)
中文名称: 维兰特罗
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl
InChI: InChI=1S/C24H33Cl2NO5/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28/h5-9,14,24,27-30H,1-4,10-13,15-17H2/t24-/m0/s1
描述信息
An organochlorine compound that is used in the form of its trifenate salt for treatment of chronic obstructive pulmonary disease.
C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist
Vilanterol (GW642444) is a long-acting β2-adrenoceptor (β2-AR) agonist with 24 h activity. The pEC50s for β2-AR,β1-AR and β3-AR is 10.37±0.05, 6.98±0.03 and 7.36±0.03, respectively.
同义名列表
2 个代谢物同义名
数据库引用编号
8 个数据库交叉引用编号
- ChEBI: CHEBI:75037
- KEGGdrug: D09696
- PubChem: 10184665
- DrugBank: DB09082
- ChEMBL: CHEMBL1198857
- CAS: 503068-34-6
- MetaboLights: MTBLC75037
- medchemexpress: HY-14300
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Yiwen Gong, Zichao Sui, Yinghua Lv, Qingshan Zheng, Lujin Li. LABA/LAMA versus LABA/ICS fixed-dose combinations in the prevention of COPD exacerbations: a modeling analysis of literature aggregate data.
European journal of clinical pharmacology.
2023 Jul; ?(?):. doi:
10.1007/s00228-023-03543-y. [PMID: 37507595] - Peter Daley-Yates, Brian Keppler, Amanda Baines, George Bardsley, James Fingleton. Metabolomic changes related to airway inflammation, asthma pathogenesis and systemic activity following inhaled fluticasone furoate/vilanterol: a randomized controlled trial.
Respiratory research.
2022 Sep; 23(1):258. doi:
10.1186/s12931-022-02164-w. [PMID: 36127726] - Meng-Jer Hsieh, Ning-Hung Chen, Shih-Lung Cheng, Chi-Wei Tao, Yu-Feng Wei, Yao-Kuang Wu, Ming-Cheng Chan, Shih-Feng Liu, Wu-Huei Hsu, Tsung-Ming Yang, Ming-Shian Lin, Ching-Lung Liu, Ping-Hung Kuo, Ying-Huang Tsai. Comparing Clinical Outcomes of Tiotropium/Olodaterol, Umeclidinium/Vilanterol, and Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy in Patients with Chronic Obstructive Pulmonary Disease in Taiwan: A Multicenter Cohort Study.
International journal of chronic obstructive pulmonary disease.
2022; 17(?):967-976. doi:
10.2147/copd.s353799. [PMID: 35510163] - Shuying Yang, Laurie A Lee, Neal Sule, Andrew Fowler, Guy Peachey. Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN).
Clinical pharmacokinetics.
2021 07; 60(7):887-896. doi:
10.1007/s40262-021-00988-1. [PMID: 33598874] - Rashmi Mehta, Colm Farrell, Siobhán Hayes, Ruby Birk, Malek Okour, David A Lipson. Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.
Clinical pharmacokinetics.
2020 01; 59(1):67-79. doi:
10.1007/s40262-019-00794-w. [PMID: 31321713] - Durgawati Patel, Kuldeep Kumar Namdev, Kanika Verma, Ritika Gururani, Akansha Tiwari, Puspendra Kumar, Rikeshwer Prasad Dewangan, Saikh Mohammad Wabaidur, Swapnil Sharma, Jaya Dwivedi. HPLC-UV and spectrofluorimetric methods for simultaneous estimation of fluticasone furoate and vilanterol in rabbit plasma: A pharmacokinetic study.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2019 Nov; 1132(?):121842. doi:
10.1016/j.jchromb.2019.121842. [PMID: 31669821] - Yan Li, Huafang Li, Yucheng Sheng, Xin Du, Yuhui Yao, Xian Luo, Peiming Ma. Pharmacokinetics of Single and Repeat Doses of Fluticasone Furoate/Umeclidinium/Vilanterol in Healthy Chinese Adults.
Clinical pharmacology in drug development.
2019 08; 8(6):721-733. doi:
10.1002/cpdd.626. [PMID: 30427594] - Bartolome R Celli, Julie A Anderson, Robert Brook, Peter Calverley, Nicholas J Cowans, Courtney Crim, Ian Dixon, Victor Kim, Fernando J Martinez, Andrea Morris, David E Newby, Julie Yates, Joergen Vestbo. Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial.
BMJ open respiratory research.
2019; 6(1):e000431. doi:
10.1136/bmjresp-2019-000431. [PMID: 31258919] - Philip D Adamson, Julie A Anderson, Robert D Brook, Peter M A Calverley, Bartolome R Celli, Nicholas J Cowans, Courtney Crim, Ian J Dixon, Fernando J Martinez, David E Newby, Jørgen Vestbo, Julie C Yates, Nicholas L Mills. Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease.
Journal of the American College of Cardiology.
2018 09; 72(10):1126-1137. doi:
10.1016/j.jacc.2018.06.051. [PMID: 30165984] - Rashmi Mehta, Michelle Green, Bela Patel, Jonathan Wagg. Concentration-QT analysis of the randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.
Journal of pharmacokinetics and pharmacodynamics.
2016 Apr; 43(2):153-64. doi:
10.1007/s10928-015-9461-x. [PMID: 26739997] - Zdenek Chundela, Joachim Große. Olodaterol and vilanterol detection in sport drug testing.
Drug testing and analysis.
2015 Nov; 7(11-12):980-2. doi:
10.1002/dta.1918. [PMID: 26593301] - Xia Chen, Xin Zheng, Ji Jiang, Pei Hu, Kai Wu, Lihong Zhuang, Lian Liu, Xin Du, Rodger Kempsford, Ann Allen. Pharmacodynamics and pharmacokinetics of fluticasone furoate/vilanterol in healthy Chinese subjects.
Pharmacotherapy.
2015 Jun; 35(6):586-99. doi:
10.1002/phar.1598. [PMID: 26059225] - Rashmi Mehta, Kelly Hardes, Noushin Brealey, Lee Tombs, Andrew Preece, Dennis Kelleher. Effect of severe renal impairment on umeclidinium and umeclidinium/vilanterol pharmacokinetics and safety: a single-blind, nonrandomized study.
International journal of chronic obstructive pulmonary disease.
2015; 10(?):15-23. doi:
10.2147/copd.s68094. [PMID: 25565796] - Chaoying Hu, Jingying Jia, Kelly Dong, Linda Luo, Kai Wu, Rashmi Mehta, Jack Peng, Yan Ren, Annette Gross, Hui Yu. Pharmacokinetics and tolerability of inhaled umeclidinium and vilanterol alone and in combination in healthy Chinese subjects: a randomized, open-label, crossover trial.
PloS one.
2015; 10(3):e0121264. doi:
10.1371/journal.pone.0121264. [PMID: 25816315] - Rodger Kempsford, Ann Allen, Philippe Bareille, Melanie Hamilton, Anne Cheesbrough. The pharmacodynamics, pharmacokinetics, safety and tolerability of inhaled fluticasone furoate and vilanterol administered alone or simultaneously as fluticasone furoate/vilanterol.
Clinical pharmacology in drug development.
2015 01; 4(1):2-11. doi:
10.1002/cpdd.160. [PMID: 27127998] - Jeff Sigler. Drug updates and approvals: 2014 in review.
The Nurse practitioner.
2014 Dec; 39(12):14-23; quiz 23. doi:
10.1097/01.npr.0000456393.83499.90. [PMID: 25350291] - Rashmi Mehta, Kelly Hardes, Dennis Kelleher, Andrew Preece, Lee Tombs, Noushin Brealey. Effects of moderate hepatic impairment on the pharmacokinetic properties and tolerability of umeclidinium and vilanterol in inhalational umeclidinium monotherapy and umeclidinium/vilanterol combination therapy: an open-label, nonrandomized study.
Clinical therapeutics.
2014 Jul; 36(7):1016-1027.e2. doi:
10.1016/j.clinthera.2014.05.002. [PMID: 24947493] - Navin Goyal, Misba Beerahee, Chris Kalberg, Alison Church, Sally Kilbride, Rashmi Mehta. Population pharmacokinetics of inhaled umeclidinium and vilanterol in patients with chronic obstructive pulmonary disease.
Clinical pharmacokinetics.
2014 Jul; 53(7):637-48. doi:
10.1007/s40262-014-0143-4. [PMID: 24756395] - Amanda Oliver, Sandi VanBuren, Ann Allen, Melanie Hamilton, Lee Tombs, Amir Inamdar, Rodger Kempsford. Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma.
Clinical therapeutics.
2014 Jun; 36(6):928-939.e1. doi:
10.1016/j.clinthera.2014.03.014. [PMID: 24793536] - Ann Allen, Isabelle Schenkenberger, Roopa Trivedi, Jeremy Cole, Wesley Hicks, Nadeem Gul, Loretta Jacques. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled study.
The clinical respiratory journal.
2013 Oct; 7(4):397-406. doi:
10.1111/crj.12026. [PMID: 23578031] - Norie Nakahara, Akira Wakamatsu, Rodger Kempsford, Ann Allen, Masanori Yamada, Shigeru Nohda, Toshiyasu Hirama. The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects.
International journal of clinical pharmacology and therapeutics.
2013 Aug; 51(8):660-71. doi:
10.5414/cp201822. [PMID: 23735179] - Rodger Kempsford, Ann Allen, Joanne Bal, David Rubin, Lee Tombs. The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenatate in healthy subjects.
British journal of clinical pharmacology.
2013 Jun; 75(6):1478-87. doi:
10.1111/bcp.12019. [PMID: 23116485] - Rodger Kempsford, Virginia Norris, Sarah Siederer. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD.
Pulmonary pharmacology & therapeutics.
2013 Apr; 26(2):256-64. doi:
10.1016/j.pupt.2012.12.001. [PMID: 23232038] - Andrew W Harrell, Sarah K Siederer, Jo Bal, Nainesh H Patel, Graeme C Young, Clive C Felgate, Sebastian J Pearce, Andy D Roberts, Claire Beaumont, Amanda J Emmons, Adrian I Pereira, Rodger D Kempsford. Metabolism and disposition of vilanterol, a long-acting β(2)-adrenoceptor agonist for inhalation use in humans.
Drug metabolism and disposition: the biological fate of chemicals.
2013 Jan; 41(1):89-100. doi:
10.1124/dmd.112.048603. [PMID: 23043183] - Ann Allen, Angela Davis, Kelly Hardes, Lee Tombs, Rodger Kempsford. Influence of renal and hepatic impairment on the pharmacokinetic and pharmacodynamic properties and tolerability of fluticasone furoate and vilanterol in combination.
Clinical therapeutics.
2012 Dec; 34(12):2316-32. doi:
10.1016/j.clinthera.2012.11.001. [PMID: 23200625] - Joseph A Boscia, Krishna K Pudi, Michael T Zvarich, Lisa Sanford, Sarah K Siederer, Courtney Crim. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
Clinical therapeutics.
2012 Aug; 34(8):1655-66.e5. doi:
10.1016/j.clinthera.2012.06.005. [PMID: 22789766]